CLLS Earnings Prediction
The chart below shows how CLLS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLLS sees a -2.44% change in stock price 10 days leading up to the earnings, and a +2.22% change 10 days following the report. On the earnings day itself, the stock moves by -1.05%. This data can give you a slight idea of what to expect for the next quarter's release.
CLLS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
CLLS Earnings Analysis
Cellectis S.A. American Depositary Shares Corporation (CLLS.O) Earnings Conference Call
Positive
Cash Position Surge: 1. Significant Cash Increase: Cellectis reported a cash position of $264 million as of September 30, 2024, up from $156 million at the end of 2023, reflecting a $108 million increase primarily due to a $140 million cash infusion from AstraZeneca.
AstraZeneca Collaboration Funding: 2. Successful Collaboration with AstraZeneca: The collaboration with AstraZeneca has triggered $47 million in funding, including $25 million upfront and $22 million from development milestones, enhancing Cellectis' financial stability.
Clinical Trial Progress Update: 3. Progress in Clinical Trials: Cellectis has completed patient identification for all 40 subjects in the BALLI-01 study, which is expected to yield Phase I data in 2025, demonstrating strong recruitment efforts.
Extended Cash Runway Strategy: 4. Extended Cash Runway: The company has extended its cash runway into 2027, supported by prudent cash management and increased revenue from collaboration partners, ensuring continued operational funding.
Favorable Safety Profile: 5. Positive Safety Profile: Cellectis has reported no dose-limiting toxicities across its clinical programs, indicating a favorable safety profile for its therapies in development.
Negative
Clinical Trial Deprioritization: 1. Deprioritized Clinical Trial: Cellectis has decided to de-prioritize the development of UCART123 for relapsed/refractory acute myeloid leukemia, indicating a shift in focus towards programs with a higher chance of success.
Rising Cash Outflows: 2. Increased Cash Burn: The company reported cash payments to suppliers totaling $42 million, including $30 million to R&D suppliers, which reflects a significant cash outflow amid ongoing development efforts.
Net Loss Announcement: 3. Net Loss Reporting: Cellectis reported a consolidated net loss attributable to shareholders for the nine months ended September 30th, 2024, although specific figures were not disclosed in the call.
Data Release Delay: 4. Delayed Data Release: The anticipated Phase I dataset for the BALLI-01 study has been pushed to 2025, indicating a delay in expected clinical progress and data availability.
Constrained Revenue Growth: 5. Limited Revenue Growth: Despite triggering $47 million under the AstraZeneca collaboration, the overall revenue growth remains constrained, with the company focusing on prudent cash management and extending its cash runway.
CLLS FAQs
How does CLLS typically perform around its earnings report dates?
Is Cellectis S.A. (CLLS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CLLS Earning Call Sentiment
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CLLS.O
2.87%Positive
The earnings call presents mixed signals. The AstraZeneca collaboration and strong cash position are positive indicators, but supply chain challenges and intense competition in cell and gene therapy pose risks. The Q&A reveals management's cautious approach to prioritizing projects and lack of clarity on future datasets. Additionally, deprioritizing UCART123 raises concerns. Despite these issues, the partnership with AstraZeneca provides a financial buffer, mitigating some negative impacts. Overall, the sentiment is neutral as positives balance out the negatives.
